Literature DB >> 2934387

von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.

Y Fujimura, K Titani, L Z Holland, S R Russell, J R Roberts, J H Elder, Z M Ruggeri, T S Zimmerman.   

Abstract

We have purified a reduced and alkylated tryptic fragment of von Willebrand factor (vWF) which migrated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a 52/48-kDa doublet, but behaved as a single 46-kDa species after partial deglycosylation. After extensive treatment with denaturants, the 52/48-kDa polypeptide retained its ability to inhibit ristocetin-induced platelet aggregation in the presence of native vWF, as well as aggregation induced by desialylated vWF alone. Therefore, the 52/48-kDa polypeptide interacts with the platelet glycoprotein Ib receptor even in the absence of ristocetin. Both the 52/48- and the 46-kDa species inhibited ristocetin-induced binding of the intact molecule to platelets, but did not affect thrombin-induced binding. Determination of the NH2-terminal sequence of both members of the doublet gave identical results: VTLNPSDPEHCQ. This provided additional evidence that differences between the doublet constituents were only of carbohydrate composition and established the position of this peptide within the vWF polypeptide chain of approximately 2050 amino acid residues as beginning with the residue tentatively designated 449. These studies suggest that native conformation is not necessary for binding of vWF to platelets at the glycoprotein Ib receptor and that a linear amino acid sequence following residue 449 defines a domain responsible for this interaction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2934387

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  An international survey to inform priorities for new guidelines on von Willebrand disease.

Authors:  Mohamad A Kalot; Mohammed Al-Khatib; Nathan T Connell; Veronica Flood; Romina Brignardello-Petersen; Paula James; Reem A Mustafa
Journal:  Haemophilia       Date:  2019-11-26       Impact factor: 4.287

2.  The linker between the D3 and A1 domains of vWF suppresses A1-GPIbα catch bonds by site-specific binding to the A1 domain.

Authors:  Alexander Tischer; Miguel A Cruz; Matthew Auton
Journal:  Protein Sci       Date:  2013-08       Impact factor: 6.725

3.  Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis.

Authors:  Takayuki Nakayama; Tadashi Matsushita; Koji Yamamoto; Noriko Mutsuga; Tetsuhito Kojima; Akira Katsumi; Norihiko Nakao; J Evan Sadler; Tomoki Naoe; Hidehiko Saito
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

4.  Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions.

Authors:  S Goto; Y Ikeda; E Saldívar; Z M Ruggeri
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

Review 5.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 6.  Laboratory diagnosis of von Willebrand disease.

Authors:  J C Roberts; V H Flood
Journal:  Int J Lab Hematol       Date:  2015-05       Impact factor: 2.877

Review 7.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

8.  Silica Nanoparticle-Endothelial Interaction: Uptake and Effect on Platelet Adhesion under Flow Conditions.

Authors:  Jiban Saikia; Raziye Mohammadpour; Mostafa Yazdimamaghani; Hannah Northrup; Vladimir Hlady; Hamidreza Ghandehari
Journal:  ACS Appl Bio Mater       Date:  2018-11-30

9.  Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Authors:  D M Larsen; S L Haberichter; J C Gill; A D Shapiro; V H Flood
Journal:  Haemophilia       Date:  2013-03-18       Impact factor: 4.287

10.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.